3,660 AbbVie Inc. $ABBV Shares Purchased by Signal Advisors Wealth LLC

Key Points

• Signal Advisors Wealth increased its AbbVie position by 16% in the third quarter, purchasing 3,660 additional shares and bringing its holdings to 26,598 shares worth approximately $6.96 million. Institutional investors own 70.23% of ABBV.
• AbbVie reported quarterly revenue of $16.99 billion and EPS of $3.65, exceeding analyst expectations, while revenue rose 10.2% year over year. The company also declared a quarterly dividend of $1.73 per share, representing a 2.5% annualized yield.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $277.18 price target, though ABBV’s elevated valuation, Humira’s sales erosion, and competition facing Skyrizi and Rinvoq remain key risks.

Signal Advisors Wealth LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 16.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,598 shares of the company's stock after purchasing an additional 3,660 shares during the period. Signal Advisors Wealth LLC's holdings in AbbVie were worth $6,958,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Corient Private Wealth LP bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $559,736,000. Legal & General Group Plc bought a new position in shares of AbbVie during the second quarter valued at approximately $2,905,952,000. Jupiter Topco LLC bought a new position in shares of AbbVie during the second quarter valued at approximately $1,560,354,000. Diamant Asset Management Inc. lifted its stake in AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company's stock worth $798,456,000 after acquiring an additional 3,654,351 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in AbbVie in the second quarter worth $817,473,000. 70.23% of the stock is owned by institutional investors.

AbbVie Trading Down 2.2%

Shares of ABBV stock opened at $274.82 on Wednesday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $283.43. The stock has a market cap of $485.55 billion, a PE ratio of 77.63, a price-to-earnings-growth ratio of 1.28 and a beta of 0.24. The company's fifty day moving average price is $260.41 and its 200-day moving average price is $237.87.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 13.95 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.5%. AbbVie's payout ratio is presently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential Q3 revenue beat: RBC expects AbbVie to exceed third-quarter revenue estimates, driven by continued momentum for immunology drugs Skyrizi and Rinvoq, as well as psychiatric medicine Vraylar. This supports expectations that newer products can offset Humira’s loss of exclusivity. AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says
• Positive Sentiment: Encouraging Skyrizi data: New Phase 3 AFFIRM results showed favorable clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with moderately to severely active Crohn’s disease. The data could strengthen Skyrizi’s position in a major growth market and expand AbbVie’s immunology opportunity. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Pipeline and analyst support: Recent Crohn’s disease data for Skyrizi and Rinvoq, cancer-related regulatory milestones for Temab-A, and early metabolic-treatment data are improving the outlook for AbbVie’s post-Humira growth. RBC reaffirmed its “Outperform” rating, although its target implies only limited additional upside. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Neutral Sentiment: Strategic expansion: AbbVie’s acquisition of Apogee and related leadership moves highlight the company’s effort to replenish its pipeline through business development, but the long-term financial impact remains uncertain. Biotech Builder Paragon Imports Apogee’s Top Brass After AbbVie Buyout
• Negative Sentiment: Valuation and execution risks: At a high earnings multiple near its recent peak, ABBV may be vulnerable to profit-taking even with positive clinical news. Investors also remain concerned about Humira’s ongoing sales erosion, increasing immunology competition, and whether Skyrizi and Rinvoq can sustain their rapid growth.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Wells Fargo & Company lifted their price target on shares of AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a report on Monday, August 17th. Weiss Ratings upgraded shares of AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Sanford C. Bernstein restated a "market perform" rating and issued a $225.00 price objective (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $277.18.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.